- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04664582
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck - A Multi-Institutional Prospective Study
Current guidelines in management of regional lymph node metastases for cSCC patients include surgical resection with or without adjuvant therapy as well as chemotherapy and interdisciplinary management; in advanced disease, supportive and palliative care is recommended. These guidelines also define the role of SLNB in management of high-risk cSCC as unclear and suggest further studies need to determine its utility and indications11.
Currently, routine practice of performing SLNB in cSCC varies across Quebec and within Canada. At many institutions, SLNB is not routinely performed on patients with cSCC. The current standard of treatment is to observe closely when a patient is deemed to have a high-risk cancer, and if they have clinical or radiological findings of lymphadenopathy, a formal surgical neck dissection is performed. Given the comorbidities and risks involved in treatment of regional lymph nodes in cSCC, the role of SLNB in cSCC patients needs further clarification. This multicentre prospective study aims to better clarify this role and formulate suggested criteria for its indications.
Study Overview
Status
Intervention / Treatment
Detailed Description
INTRODUCTION:
Cutaneous Squamous Cell Carcinoma (cSCC) is a malignant neoplasm that arises from epidermal keratinocytes. It is the second most commonly seen nonmelanoma skin cancer after basal cell carcinoma (BCC) and is one of the most common malignancies in the world. The annual incidence of nonmelanoma skin cancers exceed all other malignancies combined. It also has a predilection for the head and neck, due to being a common location for sun-exposed skin. While incidences of both BCC and squamous cell carcinoma are increasing worldwide, cSCC is increasing even more disproportionately. This increase in skin cancer trends is likely due to a combination of factors including increased sun exposure along with increasing life expectancies. Furthermore, unlike BCC which tends to have an indolent course and is rarely metastatic, cSCC has more metastatic potential than BCC. While the vast majority of cSCC cases can be treated with curative intent without complication, there are a certain subset of cSCC which behave aggressively with significant risk for local recurrence and distant metastasis.
Many retrospective studies have tried to define "high-risk" features in cSCC that are predictive of regional and distant metastasis or poor survival, including local recurrence, depth of invasion, larger size, perineural and lymphovascular invasion, poor differentiation, and immunosuppression. Despite this, there is poor concordance in current guidelines on which patient and tumor characteristics constitute high-risk features. These include discrepancies between major guiding associations, such as the American Joint Committee on Cancer and National Comprehensive Cancer Network Clinical Practice Guidelines. Ultimately, a consensus on the definition of high-risk features of cSCC is necessary in order to produce practical and precise guidelines to enhance patient care.
Sentinel Lymph Node Biopsy (SLNB) is an established prognostic procedure in determining the degree of spread of malignant cells. It is used widely in skin cancers such as melanoma, with consistent recommended guidelines by the American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO). However, no such guideline currently exists for cSCC and recommendations for its routine use is conflicting in the literature. There exist many studies concerning the use of SLNB in cSCC, most of which are small and retrospective in nature.
Two systematic reviews on the subject both revealed that prospective studies documenting high-risk features were necessary. A meta-analysis that included 36 studies by Thompson et al. narrowed down tumor depth and tumor diameter as having the most significant risk ratio for recurrence, metastasis, and disease-specific death in cSCC respectively. However, they also concluded that unified, consistent collection and reporting of risk factors in a prospective, multicentered effort was needed. Lastly, a multi-institutional prospective study was performed by Mooney at al between 2010-2017. While the study was well designed, they only looked at 5 tumor characteristics, including tumor site, diameter, depth, differentiation and invasion. It also appears that they used a blue dye technique for SLNB over radioactive tracer methods preferred at other institutions. They conclude that significant predictors of metastasis were four or more high-risk features, which may be vague depending on which predictors the treating team is considering. Furthermore, the generalizability of the study may be limited due to including only Australian institutions. No prospective multi-institutional studies have looked at a North American patient population.
This prospective multicentre study aims to clarify the role of SLNB in cSCC by identifying patient and tumour characteristics for candidacy criteria in SLNB indication.
RATIONALE:
After the introduction of SLNB by Morton and Cochran in the 1990s, many studies and trials were run to determine its role and indications, particularly in melanoma. Three landmark trials, MSLT-I, DeCOG-SLT and MSLT-II, among other studies, lead to the creation of SLNB guidelines by ASCO and SSO for melanoma patients. SLNB has been shown to provide substantial prognostic information as well as possible therapeutic effects in some cases; whereas Completion Lymph Node Dissection (CLND) has been demonstrated not to provide any survival benefits.
Current guidelines in management of regional lymph node metastases for cSCC patients include surgical resection with or without adjuvant therapy as well as chemotherapy and interdisciplinary management; in advanced disease, supportive and palliative care is recommended. These guidelines also define the role of SLNB in management of high-risk cSCC as unclear and suggest further studies need to determine its utility and indications.
Currently, routine practice of performing SLNB in cSCC varies across Quebec and within Canada. At many institutions, SLNB is not routinely performed on patients with cSCC. The current standard of treatment is to observe closely when a patient is deemed to have a high-risk cancer, and if they have clinical or radiological findings of lymphadenopathy, a formal surgical neck dissection is performed. Given the comorbidities and risks involved in treatment of regional lymph nodes in cSCC, the role of SLNB in cSCC patients needs further clarification. This multicentre prospective study aims to better clarify this role and formulate suggested criteria for its indications.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sena Turkdogan, MD
- Phone Number: 5147308461
- Email: sena.turkdogan@mail.mcgill.ca
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- Jewish General Hospital
-
Contact:
- Sena Turkdogan
- Phone Number: 5147308461
- Email: senatn@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: high risk features rendering the patient eligible for SLNB in this study will include two or more of the following clinical or pathological features:
- Immunocompromised
- Size more than 2 cm
- Depth more than 6 mm
- Poorly differentiated histology
- Perineural invasion > 0.1mm
- Extensive lymphovascular invasion
Exclusion Criteria:
- Evidence of lymph node metastasis (clinical, radiological, or pathological)
- Previous surgery altering lymphatic drainage of the head and neck, such as a prior neck dissection or prior neck irradiation
- Pregnancy of breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sentinel Lymph Node Biopsy
Lymphoscintigraphy will be ordered alongside usual pre-operative investigations.
Intra-operatively, the excision of the primary tumor will be done with the aim of histologically clear margins and appropriate closure as per routine practice at the operating surgeon's discretion.
The patients are injected with technicium 99 pre-operatively and a sentinel lymph node biopsy will be performed with a handheld gamma probe.
|
see intervention group description
|
No Intervention: Standard of Care
These patients will be treated with standard of care, which is wide local excision of the primary tumor without performance of sentinel lymph node biopsy, if not indicated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
predictive value of sentinel lymph node biopsy in cutaneous squamous cell carcinoma
Time Frame: 1 month after feasibility recruitment completed (anticipated Dec 2021)
|
1 month after feasibility recruitment completed (anticipated Dec 2021)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
disease free five year survival
Time Frame: 5 years post intervention
|
5 years post intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alex Mlynarek, MD, Jewish General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SLNB for SCC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sentinel Lymph Node
-
Massachusetts General HospitalBrigham and Women's Hospital; Society of University SurgeonsRecruiting
-
Federation of Breast Diseases SocietiesUnknown
-
Second Affiliated Hospital of Wenzhou Medical UniversityEnrolling by invitationMRI | Sentinel Lymph Node BiopsyChina
-
Acibadem UniversityUnknown
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingSentinel Lymph NodeFrance
-
Assiut UniversityNot yet recruiting
-
Shandong Cancer Hospital and InstituteUnknownSentinel Lymph Node BiopsyChina
-
Hospital DonostiaCompletedLymphedema of Limb | Sentinel Lymph NodeSpain
-
Seoul National University HospitalNational Evidence-Based Healthcare Collaborating AgencyActive, not recruitingBreast Cancer | Sentinel Lymph NodeKorea, Republic of
-
Novadaq Technologies ULC, now a part of StrykerCompletedBreast Cancer | Sentinel Lymph Node Biopsy | Lymph Node MappingUnited States, Canada
Clinical Trials on Sentinel Lymph Node Biopsy
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female
-
Gangnam Severance HospitalCompletedNeoadjuvant Chemotherapy | Micrometastases
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingConjunctival Melanoma | Porocarcinoma | Ocular Surface Squamous Neoplasia | Merkel Cell Carcinoma, Unspecified | Ocular Sebaceous Carcinoma | Ocular Basal Cell CarcinomaItaly
-
Bulent Ecevit UniversityRecruiting
-
Professor Fernando Figueira Integral Medicine InstituteCompletedUterine Cervical Neoplasms | Uterine NeoplasmsBrazil
-
The Christie NHS Foundation TrustWithdrawnSquamous Cell Carcinoma of the Anus
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Peking University People's HospitalSun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsUnknown
-
Peking University People's HospitalSun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsUnknown
-
Washington University School of MedicineTerminated